October 17, 2008 - Elixir Medical Corp. today announced results from three multicenter first-in-man studies of Novolimus ...
Stents
This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents.Â
October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting ...
October 15, 2008 - The new name and branding for MEDRAD’s interventional products division was unveiled to the public at ...
While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...
October 15, 2008 – At TCT 2008, Boston Scientific Corp. announced 12-month left main and three-vessel disease subset ...
October 15, 2008 – Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) ...
October 15, 2008 – The latest update to an independently conducted pooled data analysis shows that Medtronic’s Endeavor ...
October 14, 2008 – Medtronic released, at TCT 2008, new data from the ENDEAVOR clinical program that reinforces the ...
October 13, 2008 — Data from an independent meta-analysis of Abbott Vascular’s SPIRIT II and SPIRIT III randomized ...
October 13, 2008 - Of those treated with Medtronic’s Endeavor Resolute drug-eluting stent (DES) in the RESOLUTE IDE ...
October 13, 2008 – At TCT 2008, Boston Scientific Corp. announced results from an analysis of nearly 7,500 patients from ...
October 13, 2008 - Boston Scientific Corp. released comprehensive data for the TAXUS ATLAS clinical program, a series of ...
October 10, 2008 - Boston Scientific Corp. today said it received FDA approval to market its second-generation ...
October 9, 2008 - Boston Scientific Corp. yesterday said it completed enrollment in the PERSEUS trial, designed to ...
October 8, 2008 - SurModics Inc. today said the PROTEX Coronary Stent System incorporating SurModics’ proprietary Finale ...
CeloNova BioSciences Inc.'s CATANIA Coronary Stent System features a NanoThin Polyzene-F surface treatment.
The ...